Bumetanide prevents transient decreases in muscle force in murine hypokalemic periodic paralysis

Fenfen Wu, Wentao Mi, Stephen C. Cannon

Research output: Contribution to journalArticlepeer-review

23 Scopus citations


Objective: To test the hypothesis that inhibition of the Na-K-2Cl transporter with bumetanide will reduce the susceptibility to decreases in muscle force in a mouse model of hypokalemic periodic paralysis (HypoPP). Methods: In vitro contraction tests were performed on soleus muscle isolated from mice with knock-in missense mutations that result in HypoPP (sodium channel NaV1.4-R669H) or hyperkalemic periodic paralysis (HyperPP; sodium channel NaV1.4-M1592V). Results: Bumetanide prevented the development of weakness in 2 mM K+ and also restored force during an established attack of HypoPP. Stimulation of the Na-K-2Cl transporter via induction of hyperosmolality exacerbated the weakness seen in low K+ and was also prevented by bumetanide. Bumetanide was more efficacious than acetazolamide for preventing weakness in low K+ conditions. Decreases in force in HyperPP muscle exposed to 10 mM K+ were not prevented by treatment with bumetanide. Conclusions: The Na-K-2Cl inhibitor bumetanide was highly effective in preventing attacks of weakness in the NaV1.4-R669H mouse model of HypoPP and should be considered for management of patients with HypoPP due to sodium channel mutations. Dehydration may aggravate HypoPP by stimulating the Na-K-2Cl transporter.

Original languageEnglish (US)
Pages (from-to)1110-1116
Number of pages7
Issue number12
StatePublished - Mar 19 2013

ASJC Scopus subject areas

  • Clinical Neurology


Dive into the research topics of 'Bumetanide prevents transient decreases in muscle force in murine hypokalemic periodic paralysis'. Together they form a unique fingerprint.

Cite this